PTN $4 - Phase 3 results within days ,has low valuation of $65 million so it could double or even triple on positive results Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) https://finance.yahoo.com/news/palatin-announces-database-lock-pl9643-123000682.html Top-Line Results Expected in February